Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides

The American Journal of Medicine

Volumn 80, Issue 6, 1986, Pages 1093-1097

  Moore, Richard D ^a   Smith, Craig R ^a   Lietman, Paul S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CEFOTAXIME; NAFCILLIN; TOBRAMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IATROGENIC DISEASE; KIDNEY DISEASE; LIVER DISEASE; MALE; RANDOMIZED CONTROLLED TRIAL;

AMINOGLYCOSIDES; ANTIBIOTICS; CEFOTAXIME; DOUBLE-BLIND METHOD; FEMALE; HUMAN; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGE; NAFCILLIN; SUPPORT, NON-U.S. GOV'T; TOBRAMYCIN;

EID: 0022728614     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(86)90670-4     Document Type: Article

References (18)

1. Double-blind clinical trials of aminoglycoside-induced nephrotoxicity and ototoxicity
2. Risk factors for aminoglycoside nephrotoxicity
3. Risk factors for nephrotoxicity in patients treated with amino-glycosides
4. Aminoglycoside nephrotoxicity in cirrhosis: value of beta 2-microglobulin to discriminate functional renal failure from acute tubular damage
5. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections: a randomized, double-blind trial
6. Gentamicin therapy in renal failure: a nomogram for dosage
7. Prediction of creatinine clearance from serum creatinine
8. The pathophysiology of endotoxin shock in the primate
9. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance
10. Bias due to misclassification in the estimation of relative risk
11. Characterization of the renin-angiotensin system in decompensated cirrhosis
12. Renal kallikrein excretion in cirrhotics with ascites: relationship to renal hemodynamics
13. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasocon strictor and decreased vasodilation factors
14. Renal failure
15. Aminoglycoside inhibition of a renal phosphatidylinositol phospholipase C
16. Cytoplasmic and membrane effects of aminoglycosides
17. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides